March 23, 2021
Direct-to-consumer virtual care and mail-order prescription startup Ro is adding to its already impressive fundraising haul with a fresh $500 million investment headed by prior backers General Catalyst, FirstMark Capital and TQ Ventures, the company announced this morning.
SignalFire Torch and BoxGroup also returned to participate in the Series D round, as did new investors Altimeter, Baupost,...
March 3, 2021
Virtual care provider Ro will now be making house calls to distribute vaccines to older people and those with disabilities in New York. The company teamed up with New York State’s Department of Public Health to launch its efforts called COVID-19 Vaccine Drive.
Patients are able to schedule their appointment via the new Vaccine Drive website. The effort is currently focused on individuals 65 and...
January 28, 2021
This week Reuters reported that two more major digital health companies are discussing potential merger agreements with special purpose acquisition companies (SPACs) that would lead to multibillion dollar valuations.
The first, reported late Tuesday, is app-based patient-engagement and benefits-navigation platform Sharecare.
Per Reuters' anonymous sources, the proposed deal would see Sharecare...
December 8, 2020
Direct-to-consumer virtual health company Ro is turning to the in-home healthcare space with the acquisition of digital platform Workpath.
Founded in 2015, Workpath created a tool that can offer on-demand in-home care services through an API system. Through the app virtual care providers can request to send in-home blood draws or in-home nurse visits to a patient.
The company’s API is able to...
July 28, 2020
Direct-to-consumer virtual health company Ro announced Monday it’s $200 million Series C funding round. With these additional funds, the company is now valued at $1.5 billion.
The existing investor, General Catalyst, led the round with participation from FirstMark Capital, Torch, SignalFire, TQ Ventures, Initialized Capital, 3L, BoxGroup and the Chernin Group. Ro has raised $376 million since its...
June 17, 2020
Consumer virtual health and wellness brand Ro highlighted a new partnership with healthcare API company Ribbon Health that will help users and their virtual providers seek out in-person primary and specialty care services in their area. Accessible within the telehealth platform, the new capability is available across the U.S., and includes information on the types of insurance accepted at each...
May 19, 2020
Ro, a direct-to-consumer virtual health startup best known for its sexual health products, is dipping into the dermatology space. Patients will now be able to use the service for prescription products that include eczema treatment, medical-grade antiperspirant, and prescription dandruff shampoo.
The company will also be rolling out a “nightly defense skincare” that is a custom prescription...
February 26, 2020
Direct-to-consumer virtual health company Ro is now offering allergy care. The launch means that users of Roman and Rory will be able to get prescription allergy medications through the platform’s telemedicine model.
While the company said that the new service will not be treating food allergies or uncontrolled asthma, it will cover seasonal allergies, including conditions like hay fever. ...
February 13, 2020
Direct-to-consumer virtual health company Ro launched a new health information platform dubbed Health Guide.
Currently the platform covers sexual health, hair loss, weight management, diabetes, and men’s health. However, a representative from the company said that in the future, the plan is to expand the offerings to not only cater to male users, and to include more conditions.
December 17, 2019
Ro, a direct-to-consumer virtual health company, is diving into the weight management space with the launch of a new product offering aimed at helping patients shed the pounds.
Ro, best-known for its online platform that specializes in men’s health, is now going to be offering Plenity, a new weight management product. Plenity landed FDA clearance last April and is classified as a Class II...